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The cellular immune response is characterized by the complex interaction of
many different cells responding to multiple extracellular signals. Activation,
proliferation, and directed migration ofboth local and blood-borne cells is partly
regulated by soluble mediators released by cells, referred to collectively as
cytokines. IFN-y, a glycoprotein secreted from activated T cells, has potent
immunomodulatory activities and is an important activator of the cellular im-
mune response (reviewed in reference 1). In fact, local intradermal injections of
IFN-y have been shown to elicit certain features of the delayed-type hypersen-
sitivity reaction, such asinduration, T cell and monocyte infiltration, keratinocyte
proliferation, and dermal and epidermal HLA-DR antigen expression (2).
To begin to address the molecular mechanisms that underly the biological
activity of IFN-y in the immune response, we have isolated and characterized
several genes that are induced in human cells by IFN-y (3). The deduced amino
acid sequence of one such gene, referred to as IP-10, is predicted to specify a
secreted polypeptide of 10 kD (4). The expression ofthe IP-10 gene is an early,
primary, transient response to IFN-y stimulation of responsive cells. Transcrip-
tion is induced as early as 30 min after IFN-y treatment of cells and mRNA
accumulation peaks by 5 h. IP-10 mRNA is induced >30-fold in a variety ofcells,
including mononuclear cells and fibroblasts.
The primary aminoacid sequence ofthepredicted IP-10 protein demonstrates
significant homology to a newly emerging family ofchemotactic and mitogenic
proteins associated with inflammation and cell proliferation. This family of
proteins includes: platelet factor 4 (PF4)' (5); the platelet basic proteins (0-
thromboglobulin [6] and connective tissue-activating peptide III [7]); 9E3, a
protein induced by Rous sarcoma virus transformation and associated with
proliferating fibroblast monolayers (8); and 310c, a protein induced in leukocytes
by the mitogen staphylococcal enterotoxin A (9). The genomic organization of
the IP-10 gene, when compared with the organization of the rat PF4 gene,
indicates that these genes evolved from a common ancestor (10). In fact, the
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entire protein family most likely evolved from a common ancestral gene by gene
duplication, establishing a novel gene family of chemotactic and mitogenic
cytokines, which are released from a variety of cells in response to diverse
biological stimuli.
The association of the IP-10 protein with this family of cytokines suggests
possible biological functions for this protein in an inflammatory response, which
may account for some of the diverse activities seen during the progression of a
cellular immune response. In this and an accompanying paper (11) we have
begun to address the function, localization, and processing of the IP-10 protein.
Through the production of polyclonal, monospecific antisera directed against a
recombinant IP-10 protein expressed in Escherichia coli and a synthetic peptide
synthesized to the COOH-terminus ofthe protein, the biosynthetic steps resulting
in the secretion of the IP-10 protein have been elucidated. Kaplan et al. (11)
describe the results of in vivo studies in which the expression ofthe IP-10 protein
induced during the course of a delayed-type hypersensitivity reaction in the skin
and after intradermal injection of IFN-'Y is followed. These studies suggest an
association between this protein and the development of a cellular immune
response.
Materials and Methods
Cell Culture.
￿
Human endothelial cells were isolated from umbilical cord veins (12) and
grown in M 199 medium supplemented with 20% heat-inactivated human serum, penicillin
(100 U/ml), and streptomycin (100 ag/ml). All the experiments presented in this study
were performed on second-passage human umbilical cord endothelial cells (HUVE). A
primary keratinocyte cell line isolated from human foreskin was obtained from Clonetics
Corporation (Boulder, CO) and maintained in a defined keratinocyte growth medium
(13). PBMC were isolated from venous blood fractionated on a Ficoll-Hypaque gradient.
Monocytes were isolated from these PBMC by Percoll gradient fractionation (14) and
maintained in a-modified Eagle's medium (aMEM) supplemented with 10% heat-inacti-
vated autologous human serum or FCS, penicillin, and streptomycin. FS4 cells were grown
in aMEM supplemented with 10% FCS, penicillin, and streptomycin.
All induction experiments were performed in the regular cell growth medium, using
cellsjust before reaching confluence. Monocytes were induced at 106 cells/ml in Teflon
dishes.
IFN-y.
￿
The IFN used in this study was highly purified recombinant protein synthesized
in E. coli generously provided by Genentech, Inc., San Francisco, CA. The endotoxin
levels were determined in a limulus amoebocyte lysate assay before shipping. The human
rIFN-y had a specific activity of 2-4 X 107 U/mg as determined in a human lung
carcinoma A549 inhibition assay using the encephalomyocarditis virus.
Peptide Synthesis.
￿
The peptide was synthesized by the solid-phase method (15) using
chloromethylated, 1 % crosslinked, styrene-divinylbenzene copolymer (Merrified Resin).
Deprotection was followed by a coupling program that used the symmetric anhydrides of
the appropriate Boc amino acids (Bachem Inc., Torrance, CA; or Peninsula Laboratories,
Inc., Belmont, CA) (16). The side-chain functionalities were protected by benzyl-type
protecting groups. The peptide was cleaved from the resin and deprotected by treatment
with liquid HF-anisole at ^-0°C (17). The peptide was purified by gel-permeation chro-
matography, ion-exchange chromatography, and reverse-phase HPLC. The final product
was homogeneous by analytical reverse-phase HPLC.
The peptide was glutaraldehyde coupled to keyhole limpet hemocyanin (KLH) (18). 2
Wg of peptide was dissolved 10 A,1 of H2O and added to 15 ng KLH in 2 ml 0.1 M PBS.
Glutaraldehyde (21 mM) was added over 1 h at room temperature. The mixture was
allowed to stand overnight at room temperature and then was dialyzed against PBS.1086)
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^-100 rug of protein in CFA was used to immunize two 8-wk-old female New Zealand
white rabbits. The rabbits were boosted twice at 1-mo intervals with the same amount of
protein in IFA. 10 d after the second boost, the rabbit was bled and serum was isolated
and used for Western blotting and immunoprecipitation.
Polyacrylamide Gel Electrophoresis (PAGE). SDS-PAGE was performed according to
the method of Laemmli (19) using slab gels with 10, 12.5, and 15% polyacrylamide.
A modification of the Laemmli gel system was used for gels that had to be dryed
down because of gel cracking problems. This modified SDS-PAGE system uses a lower
ratio of bisacrylamide to acrylamide (20). For samples that contained "S, gels were
processed for fluorography using Enhance (DuPont Co., Wilmington, DE) and exposed
at -70°C on Kodak x-ray film.
E. coli Expression and Production of Antiserum.
￿
A 576-bp Xba I-Eco RI derived from
the IP-10 cDNA plasmid pIFN-y-31 .7 (4) was cloned into the fusion expression vector
pB4+ (21). The pB4' vector contains the gene for the influenza viral protein NSI. The
plasmid was transformed into the E. coli strain AR58, which is a X lysogen containing a
temperature-sensitive mutation in the CI gene (C1857). The resulting strain, harboring
the recombinant expression plasmid, produced a fusion protein at the nonpermissive
temperature that consisted of 81 amino acids of NSI and 72 amino acids of IP-10.
A 325-bp Fnu4H fragment derived from the IP-10 cDNA plasmid pIFNti 31 .7 was
cloned into the nonfusion expression vector pT17. This recombinant plasmid was trans-
formed into the E. coli strain AR58, which upon temperature induction synthesized 88
amino acids of the IP-10 protein.
Bacterial cells were grown in L-broth at 30'C to an OD650 of 0.3, then shifted to 42 0C
for 1 h of growth . The bacterial cells were pelleted by centrifugation and resuspended in
1/20 vol of PBS. The cells were lysed by sonication and subjected to centrifugation at
10,000 rpm for 5 min. The pellet, which included the recombinant proteins and cellular
envelopes, was suspended in sample buffer and subjected to preparative SDS-PAGE. The
gel was stained with Coomassie Brilliant Blue R for 1 min and immediately washed five
times in deionized water. The faintly stained band was excised from the gel with a razor
blade and minced. The gel pieces were soaked for 24 h in 50 mM Tris, pH 7.5, containing
0.15 M NaCl and 0 .1 % SDS. The amount of eluted protein recovered was estimated by
comparison to protein standards (Bio-Rad Laboratories, Richmond, CA) after SDS-PAGE.
This treatment of the sample resulted in a preparation highly enriched for recombinant
proteins.
^-100 ug of protein in CFA was used to immunize an 8-wk-old female New Zealand
white rabbit. The rabbit was boosted twice at 1-mo intervals with the same amount of
protein in IFA. 10 d after the second boost, the rabbit was bled and serum was isolated
and used for Western blotting and immunoprecipitation.
IgG was isolated from serum by protein A-Sepharose affinity chromatography (Phar-
macia Fine Chemicals, Piscataway, NJ). I mg of the gel-purified recombinant protein was
coupled to cyanogen bromide-activated Sepharose 4B (Pharmacia Fine Chemicals). 100-
200 mg IgG was affinity purified on the recombinant protein column. The bound IgG
was eluted with 1 M glycine-HCI, pH 2.8, quickly neutralized with 2 M Tris, and dialyzed
against PBS. The affinity-purified antiserum was used for immunoprecipitation, immu-
nofluorescence, and immunohistochemistry.
Pulse-chase Experiments.
￿
HUVE cell monolayers (^-106 cells) were washed twice with
PBS and maintained for 30 min in aMEM lacking methionine but containing 200 mM
glutamine. Cells were then pulsed for 30 min in this cell-starvation medium supplemented
with ["S]methionine (500 uCi/ml). After removal of the pulse medium, the cells were
washed twice with PBS and then incubated with cell growth medium supplemented with
unlabeled methionine (5 mM) for the chase periods indicated. At the completion of the
chase, the monolayers were washed twice with PBS and scraped into an SDS solution
(0.5% SDS, 50 mM Tris, pH 7 .4, 100 mM NaCl, 2 mM EDTA). After being heated for
2 min at 100'C, the samples were frozen at -20°C . For immunoprecipitation, the samples
were again heated for 2 min at 100° C, sonicated for 2 min, and adjusted to contain 0.2
U/ml aprotinin (Sigma Chemical Co., St. Louis, MO), and 1 mM PMSF (Sigma ChemicalLUSTER AND RAVETCH
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Co.). Affinity-purified antibodies were added to a final concentration of 5 ug/ml and the
immunoprecipitation was continued as described below.
Immunoblotting.
￿
E. coli cells or human cell lysates (prepared as described) were dis-
solved in sample buffer (2% SDS/0.0625 M Tris, pH 7.4/10% glycerol/0.01% brom-
phenol blue/and 5% 2-ME), boiled for 5 min, and fractionated by SDS-PAGE using slab
gels of 12.5 and 15% acrylamide. Prestained protein molecular weight standards (Bethesda
Research Laboratories, Gaithersburg, MD) were used to calculate apparent molecular
weights. Protein was transferred electrophoretically to nitrocellulose (Schleicher & Schuell,
Inc., Keene, NH). All of the following steps were performed in Tris-buffered saline (TBS;
50 mM Tris, pH 7.5, 2 mM EDTA, 0.15 M NaCl), 0.5% NP-40, and 0% FCS. The
nitrocellulose filter was first treated overnight in 5% nonfat dry milk, followed by
incubation for 2 h with a 1 :1,000 dilution of antiserum. The nitrocellulose was washed
and reacted for 1 h with 106 cpm/ml of '251 Staphylococcus protein A (Amersham Corp.,
Amersham, Arlington Heights, IL). After extensive washing in TBS + 0.5% NP-40, the
filter was exposed to x-ray film at -70°C in the presence of an intensifying screen.
Immunoprecipitation. ^-106 cells were lysed in PBS containing 1% NP-40, 0.2 U/ml
aprotinin, 1 mM PMSF, and 0.1% diisopropylfluorophosphate (Sigma Chemical Co.).
Nuclei and debris were removed by centrifugation at 14,000 g for 5 min. The lysate was
adjusted to 0.2% SDS and boiled for 5 min at 100°C. The lysate was further clarified by
centrifugation at 45,000 g, 15 min at 4°C. The supernatant was passed through a 0.45-
tm millex filter and further clarified by centrifugation at 45,000 g, 15 min at 4°C.
Affinity-purified antibodies were added to a final concentration of 5 wg/ml to both lysate
and supernatant. The solution was incubated at room temperature for 4-16 h. Antigen-
antibody complexes were precipitated by incubation with protein A-Sepharose for 2 h at
room temperature.
The immunoabsorbed protein A-Sepharose beads were collected by centrifugation,
washed twice in buffer that contained 0.6 M NaCl, 0.0125 M KP04, pH 7.4, and 0.02%
NaN3 (HSA buffer), twice at room temperature with a mixed detergent solution (0 .05%
NP40, 0.1% SDS, 0.3 M NaCl, and 10 mM Tris-HCI, pH 8.6), once again with HSA
buffer, and finally, once in PBS. The antigen-antibody complexes were released from the
beads by incubation at 100° C for 2 min in 2X PAGE sample buffer.
NH2-Terminal Sequence Determination.
￿
Human keratinocytes were biosynthetically la-
beled with [sH]leucine and [96S]cysteine for 8 h. Radiolabeled IP-10 was purified from
the keratinocyte media by immunoprecipitation and SDS-PAGE. The gels were dried
down without fixing or staining. The IP-10 protein was located in the gel by autoradiog-
raphy, electroeluted from the gel, and concentrated by precipitation (22). Samples were
subjected to automated Edman degradation in Gas Phase Sequencer (Model 470A;
Applied Biosystems, Inc., Foster City, CA). The amino acid derivative obtained at each
cycle was dissolved in 20% acetonitrile and transferred to 10 ml ofAquasol for scintillation
counting.
ELISA. The antipeptide antisera were checked for their ability to react with the
synthetic peptide by an ELISA assay. Microtiter plates were coated with peptide (100
ng/well) in a sodium carbonate buffer, pH 9.6, and then saturated with 3% BSA, PBS,
0 .1 % Tween 20. 100 tsl of antipeptide antisera dilutions from 10-2 to 10-7 were placed
in the wells and incubated for 2 h. After extensive washing in PBS/0.05% Tween, the
plates were incubated for 2 h with peroxidase-labeled affinity-purified goat anti-rabbit
IgG. The wells were then washed and the substrate O-phenylenediamine (100 Al of 10
mg/25 ml in 0.05 M citrate phosphate buffer, pH 5) was added. The reaction was allowed
to proceed for 10 min at room temperature and was stopped by addition of 50 ml of 2 .5
M H2SO4. Absorbance was read at 410 nm in an automatic plate reader (Minireader II;
Dynatech Laboratories, Inc., Alexandria, VA). Positive ELISA readings were obtained at
dilutions of 10-7 after boosting with peptide conjugate. The purified peptide was attached
to CNBr-activated Sepharose 4B. This matrix was used to affinity purify the rabbit
antipeptide antiserum. The affinity-purified antibodies were used for Western blotting
and immunoprecipitation experiments.
RNA Isolation and Blotting. Total cellular RNA was isolated by the guanidinium1088
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isothiocyanate-cesium chloride method (23). RNA was fractionated on a 1% agarose gel
containing 2.2 Mformaldehyde (24) and transferred to nitrocellulose (25)and hybridized
with a random primed (26) IP-10 cDNA probe (pIFN7-31.7). Hybridization was per-
formed at 40°C for 16 h in a solution containing 50% formamide, 10% dextran sulfate,
5X SSC (IX SSC: 0.15 M sodium chloride, 0.015 M sodium citrate), 1X Denhardt's
(0.02% polyvinyl-pyrrolidone, 0.02% Ficoll, and 0.02% BSA), and 200,ug/ml ofsonicated
herring sperm DNA. The filters were washed at 50°C in 0.1X SSC containing 0.1% SDS
and exposed at -70°C to Kodak XAR film in the presence of one intensifying screen
(Cronex Lightning Plus).
Results
Peptide Synthesis.
￿
A peptide was synthesized to the carboxyl 22 amino acids
ofthe deduced IP-10 protein. The carboxyl 22 amino acids were chosen for two
reasons. First, the carboxyl 13 amino acids ofthe homologous protein PF-4 have
been reported to be biologically active in chemotactic chambers (27). Second,
Chou-Fasman computer analysis (28) strongly predicts an amphiphilic a-helical
COOH-terminus for the IP-10 protein. Since some amphiphilic a-helixes are
stable in aqueous solution (29, 30), this COOH-terminal 22-amino-acid peptide
could exist as an a-helix in an aqueous environment. It is possible then that this
peptide could mimic the secondary structure of the COON-terminus of the
native polypeptide. This would theoretically make it an ideal immunogen.
The COOH-terminal 22 amino acids were synthesized using the solid-phase
method (15). After completion of the synthesis and HF cleavage from the resin,
the peptide was purified by gel filtration, ion exchange, and finally, reverse-
phase HPLC. The peptide was then glutaraidehyde-coupled to KLH and used
to elicit a monospecific polyclonal rabbit antiserum. The polyclonal antibodies
reacted very strongly with the peptide in solid-phase ELISA assays (data not
shown). Nonetheless, they did not Western blot or immunoprecipitate a product
from IFN-'Y-induced human cells. This result can be explained in one of two
ways: Either the antipeptide antibodies are not reactive with the IP-10 protein
or the IP-10 protein undergoes C001-1-terminal processing, removing from the
mature polypeptide the region chosen as the synthetic immunogen.
E. coli Expression.
￿
To resolve the issue proposed above for the antipeptide
antiserum's inability to recognize the predicted human protein, the IP-10 open
reading frame was expressed in E. coli and the recombinant protein purified by
SDS-PAGE and used to elicit a polyclonal monospecific antiserum. The open
reading frame of the IP-10 cDNA was first expressed as a fusion protein with
the influenza nonstructural protein NS1 (Fig. 1, lane 2). This fusion protein was
purified by elution from SDS-polyacrylamide gels (lane 3) and then used to
immunize rabbits. Subsequently, IP-10 was expressed as a nonfusion protein,
purified from SDS-polyacrylamide gels (Fig. 2B), coupled to CNBr-activated
Sepharose, and used to affinity purify the high titer NS1-IP-10 antiserum. This
resulted in affinity-purified polyclonal antibodies directedagainst theentire open
reading frame of IP-10.
To determine the reactivity ofboth the antipeptide and the anti-recombinant
IP-10 antibodies, the E. coli lysate expressing IP-10 was subjected to Western
blot analysis using these antibodies (Fig. 2A). Both the antipeptide and the anti-
rIP-10 antibodies recognize the E. coli-synthesized nonfusion IP-10. This indi-LUSTER AND RAVETCH
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FIGURE 1 . E. coli expression
and purification ofthe NS 1-IP-10
fusion protein . (Top) 12.5% SDS-
PAGE analysis of E. coli lysates
expressing the NS I protein alone
(lane 1), E . coli lysates expressing
the NSI-IP-10 fusion protein
(lane 2), the purified NS1-IP-10
protein (lane 3), and molecular
weight markers (X 10'') (lane 4) .
The gelwas stained with Coomas-
sie Brilliant Blue. (Bottom)A sche-
matic of the IP-10 cDNA where
the rectangle indicates coding se-
quence and the hatched rectangle
indicates the predicted signal se-
quence . A schematic of the
expression vector used to con-
struct the NSI-IP-10 fusion is also
depicted. Numbers refer to the
predicted amino acid sequence
beginning with the initiating me-
thionine (4) .
FIGURE 2 . E . coli expres-
sion, immunoblot, and purifi-
cation of the nonfusion IP-10
protein . (Top) (A) Immunoblot
of paired extracts of E. coli
lysates, control (lane 1), and
those expressing the IP-10
protein (lane 2) were fraction-
ated by 15% SDS-PAGE. Pro-
teins were electrophoretically
transferred to nitrocellulose
and reacted with a 1 :1,000 di-
lution of the indicated anti-
serum followed by "l-Pro-
tein A (106 cpm/ml) and sub-
jected to autoradiography .
Control lysates were isolated
fromE . coli cells harboringan
expression plasmid that con-
tained the IP-10cDNA in the
reverse orientation inserted
into the expression site. Ly-
satesfrom the control and ex-
pressing E . coli were prepared
identically from -8 X 10' bac-
teria. M, X 10' markers are
indicated on the right . (B)
Coomassie Brilliant Blue stained 15% SDS-PAGE of the purifiedE . coli-expressed nonfusion IP-10
protein . M, markers (X 10'') are indicatedon the left. (Bottom)A schematic of thecDNA is presented
indicating the region of the IP-10 protein to which the synthetic peptide was synthesized . The
rectangle indicates coding region and the hatched rectangle indicates the predicted signal sequence .
Below this schematic, another schematic illustrates the nonfusion expression vector and the particular
construct used in the experiment shown inA. Numbers refer to the predicted amino acid sequence
beginning with the initiating methionine (4).1090
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FIGURE 3 .
￿
Immunoprecipitation analysis of biosyn-
thetically labeled HUVE. HUVE cells were induced
with 100 U/ml rIFN-y for 5 h in their regular growth
medium . This medium was removed from the cells
and replaced with aMEM lacking methionine but
containing 5% FCS, 200 mM glutamine, 500 PCi/ml
[ s5S]methionine, and 200 U/ml rIFN-y . After a 10-h
labeling, the cell lysates and supernatants were im-
munoprecipitated with the indicated antibody . NRS,
normal rabbit serum, was the pooled preimmune ser-
ums from 4 rabbits : the two rabbits used to elicit the
antipeptide antiserum and the two rabbits used to
elicit the anti-rIP-10 antiserum . (-) Immunoprecipi-
tates of cells that were not treated with rIFN-y. (+)
Immunoprecipitates of rIFN-y-treated cells as de-
scribed above. Immunoprecipitates were fractionated
on a 15% low bisacrylamide SDS-polyacrylamide gel
treated with Enhance and exposed for 3 d.
cates that the antipeptide antibodies recognize the predicted open reading frame
encoded by the IP-10cDNA .
Immunoprecipitation Analysis. However, when these antibodies are used to
immunoprecipitate (Fig . 3) or Western blot (data not shown) IFN-.y-induced
human cells, only the anti-rIP-10 antibodies recognize a human polypeptide .
HUVE cells were either induced with 100 U/ml IFN-y for 4 h in their regular
growth medium containing 20% human serum, or left untreated and then
biosynthetically labeled for 10 h with [s5S]methionine (Fig . 3) . During this
labeling, 94% of theimmunoprecipitable protein is found in the cell supernatant,
confirming the prediction based on thecDNA sequence that IP-10 is a secreted
polypeptide . In addition, it is evident that the synthesis and secretion of this
protein is profoundly induced in endothelial cells by IFN-'y . However, the form
immunoprecipitated from endothelial cells migrates as a 6-7-kD doublet on
reducing SDS-PAGE and not as the predicted 10-kD polypeptide, suggesting
that posttranslational processing may be occurring.
Since the cDNA sequence of IP-10 predicts a 10-kD secreted polypeptide
containing four cysteines, the 6-7-kD doublet immunoprecipitated from IFN-y-
induced endothelial cell lysates and supernatants might exist natively as a 12-kD
disulfide-crosslinked polypeptide migrating in SDS-polyacrylamide gels . To ad-
dress this possibility, the endothelial cell immunoprecipitates were analyzed by
nonreducing SDS-PAGE (Fig . 4) . Under nonreducing conditions, three bands
that migrate very tightly around 6 kD are evident in the cell supernatant . The
two fastest migrating bands seen under nonreducing conditions comigrate with
the two bands seen under reducing conditions . This suggests that there is a small
disulfide-linked peptide, attached to one or both of the 6-7-kD forms, that
accounts forthe slowest migrating band seen only under nonreducingconditions .
NH2-Terminal Sequence Analysis of Secreted IP-10 .
￿
NH2-terminal sequence
analysis wasperformed on the IP-10 protein secreted from human keratinocytes .LUSTER AND RAVETCH
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FIGURE 4 .
￿
Immunoprecipitable IP-10 analyzed by nonreducing (-2-
ME) and reAucing (+2-ME) SDS-PAGE. rIFN-y HUVE cell lysate (L)
and supernatant (S) was Immunoprecipitated as described in Materials
and Methods . Theantigen-antibody complexes were released from the
protein A-Sepharose beads by incubation in 2X PAGE sample buffer
without (-) 2-ME, and with (+) 2-ME. Samples were fractionated by
15% low-bis SDS-PAGE, treated with Enhanceandexposed for 14d.
FIGURE 5 .
￿
Formsof IP-10 synthesized in vivo in a pulse-chase experiment . -106 HUVE cells
were pulsed with ["Slmethionine, and the label waschased with unlabeled methionine for the
time periods indicated in hours . Immunoprecipitated proteins were subjected to 15% low
SDS-PAGE, treated with Enhance, and exposed for 21 d. (Lane 1) In vivo-labeled immuno-
reactive products isolated immediately after a 30-min pulse ; (lanes 2-5) As in lane 1 except
that the 30-min pulse was followed by a2-h chase for lane 2, a4-h chase for lane 3, a8-h chase
for lane 4, anda 16.5-h chase for lane S, "C-labeled molecular weight markers were obtained
from Bio-Rad Laboratories.
Keratinocyte monolayers were simultaneously biosynthetically labeled with [sH]-
leucine and [s5S]methionine . The IP-10 protein was purified by immunoprecili-
itation and subsequent SDS-PAGE and then subjected to 20 consecutive cycles
of automated Edman degradation . The secreted mature form of IP-10 shows a
Leu at position 3 and Cys at positions 9 and 11 . These positions coincide with
the amino acid sequence predicted by the cDNA sequence (4) . This confirms the
prediction for the signal peptidase cleavage site based on the cDNA sequence
analysis . In addition, it definitively establishes that the anti-rIP-10 recognizes IP-
10 synthesized and secreted from human cells .
Posttranslational Processing.
￿
A pulse-chase experiment was performed using
HUVE cells to address the biosynthetic relationship between these various forms
of immunoprecipitable IP-10 (Fig . 5) . Essentially identical results are obtained1092
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when the pulse-chase experiments are analyzed by reducing and by nonreducing
SDS-PAGE, so only an autoradiogram of the nonreducing gel is presented (Fig.
5). Immunoprecipitation following a 30-min in vivo labeling with [s5S]methionine
reveals only the 6-7-kD forms in the cell lysate. During this 30-min labeling,
^-50% of the immunoprecipitable material is found in the cell supernatant. This
indicates that IP-10 is synthesized and secreted in <30 min . After 2 h of chase,
very little of the IP-10 protein can be immunoprecipitated from the cell lysate;
it is either secreted or degraded; it is not stored intracellularly. The extracellular
form of IP-10 seems to be processed over time in the culture medium. After
16.5 h of chase, ~50% of the immunoprecipitable material seen after 30 min of
labeling still remains immunoprecipitable . In addition, IP-10 appears to undergo
further processing once secreted, as is evident from its faster mobility at later
times during the chase.
The predicted unprocessed forms of IP-10, however, are not evident from
these experiments. After a 30-min labeling (Fig. 5), or after a 10-h labeling (Fig.
3), the largest form of immunoprecipitable IP-10 is 7 kD. Hybrid selection (4),
cDNA sequence (4) and E. coli expression (Figs. 1 and 2) indicate that the primary
translation product of the IP-10 protein is 12 kD. The predicted signal peptidase
cleavage would then produce a 10-kD polypeptide. Thus, it appears that the
proteolytic processing of IP-10 is too rapid to capture the predicted unprocessed
12-kD and 10-kD forms of the IP-10 protein using this type of immunoprecipi-
tation analysis in primary endothelial cells.
Inducible Expression of the IP-10 Protein and RNA in Human Cells.
￿
To deter-
mine the generality of the secretory and protein processing patterns seen with
HUVE cells, immunoprecipitation analysis was performed on several other
primary human cells (Fig. 6). Parallel cultures of human monocytes, fibroblasts,
and keratinocytes were either left untreated or induced with 100 U/ml of IFN-
y for 4 h and then biosynthetically labeled with [s5S]methionine for 10 h. The
cell lysates and supernatants were immunoprecipitated using the anti-rIP-10
antibodies and analyzed by SDS-PAGE. The three additional cell types examined
reveal a pattern of induction, secretion and processing of the IP-10 protein
similar to that seen with HUVE cells. Densitometric scanning of autoradiograms
containing immunoprecipitated IP-10 reveals that keratinocytes secrete -3 times
more IP-10 than endothelial cells, 33 times more IP-10 than monocytes, and
165 times more IP-10 than fibroblasts.
Total cellular RNA isolated from control and rIFN-y-stimulated primary
HUVE cells, monocytes, and keratinocytes was analyzed for the expression of
the IP-10 mRNA (Fig. 7). The cells examined are stimulated by IFN-'Y to
accumulate the IP-10 mRNA in a manner consistent with the pattern of IP-10
protein induction (Figs. 3 and 6).
Discussion
In this study we have generated polyclonal monospecific antiserum to an rIP-
10 protein synthesized in E. coli and have demonstrated that IFN-1' alone induces
the de novo synthesis and subsequent constitutive secretion of the IP-10 protein
from a variety of human cells, including endothelial cells, monocytes, fibroblasts,
and keratinocytes. The four cell types tested, however, do not synthesize andLUSTER AND RAVETCH
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FIGURE 6 .
￿
Inducible secretion of the IP-10 protein from human cells : immunoprecipitation
analysis of primary fibroblasts, monocytes, and keratinocytes . The cells were biosynthetically
labeled with [s6S)methionine and then used for immunoprecipitation analysis as described in
Materials and Methods . ^-106 cells were used for each immunoprecipitation . The fibroblasts
samples were analyzed by 15% SDS-PAGE under reducing conditions and the monocyte and
keratinocyte samples were analyzed by 15% SDS-PAGE under nonreducing conditions . The
SDS-PAGE gels were treated with Enhance and subjected to autoradiograph, the fibroblast
gel was exposed for 21 d, the monocyte gel for 6 d, and the keratinocyte gel for 14 d.
FIGURE 7 . IFN--y inducibility of
the IP-10mRNA in human cells . To-
tal cellular RNA was isolated (22)
from control and rIFN-1 treated
HUVE, human monocytes (MO) and
human keratinocytes (Ker) . 2 Ag of
HUVE and 10 kg of MO and Ker
total RNA was fractionated on a 2.2
M formaldehyde/1% agarose gel,
transferred to nitrocellulose, and hy-
bridized with a nick-translated IP-10
cDNA probe. The migration of 28s
and 18s ribosomal RNA is indicated .1094
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FIGURE 8. Hypothetical
model of the predicted pri-
mary structure of the IP-10
protein. The NH s-terminal
valine is predictedfrom signal
peptidase cleavage. The disul-
fide structure is that deter-
mined for,6TG superimposed
on the IP-10 protein . Arrows
indicate sites of potential
cleavage that are predicted to
occurbasedon mobility of the
IP-10 protein in SDS-PAGE
and the inability of the
COOH-terminal directed an-
tipeptide antibody to immu-
noprecipitate a product from
humancells.
secrete equal amounts of IP-10 protein after IFN-y treatment. Of the cells tested,
keratinocytes induced by IFN-y secrete the most IP-10, with endothelial cells,
monocytes, and fibroblasts secreting lesser amounts of IP-10, in that order. This
is consistent with the amount of IP-10 mRNA that accumulates in these cells
after IFN-y treatment. This suggests that IP-10 mRNA accumulation is an
accurate reflection and the primary determinant of the amount of IP-10 protein
secreted by cells.
Immunoprecipitation of biosynthetically labeled cells and radiochemical se-
quence analysis indicate a complex posttranslational processing pattern for the
IP-10 protein, including signal peptidase cleavage and COOH-terminal process-
ing. Based on the data presented here and the disulfide structure of the homol-
ogous protein ,Q-thromboglobulin (QTG) (6), a model is presentedfor thedisulfide
structure and processing of IP-10 (Fig. 8).
/OTG is found in the serum as a homotetramer of four noncovalently associated
chains, each containing two intrachain disulfide bonds; no free sulfhydryl groups
are detected in OTG with 5,5'-dithio-bis-2-nitrobenzoic acid. The disulfide
structure of #TG was deduced from amino acid analysis of CNBr and Staphylo-
coccal protease cleavage fragments of OTG. Disulfide bridges link cysteine 16 of
the mature ,#TG polypeptide to cysteine 42 and cysteine 18 to cysteine 58. After
signal peptidase cleavage, the processed form of IP-10 is predicted to contain
four cysteines that align perfectly with OTG and PF-4 . It is not unreasonable to
suspect then, that IP-10 will fold into a disulfide structure analogous to OTG.
This is illustrated diagramatically in Fig. 8, with cysteine 9 of the mature
polypeptide disulfide-linked to cysteine 36 and cysteine 11 disulfide-linked to
cysteine 53 .
One possible processing pattern consistent with the data presented here is
illustrated in Fig. 8. There are three consecutive lysines beginning at residue 46
and a lysine followed by an arginine at residue 51 and 52 that are potential
cleavage sites for dibasic endopeptidases. If the lys-lys bonds are less susceptible
to digestion than the lys-arg bond, cleavage at these two positions would produce
the 6-7-kD doublet that is seen when immunoprecipitates are analyzed under
reducing conditions. An additional cleavage carboxyl to cysteine 53 would leavea small peptide disulfide-linked to both of the carboxyl trimmed mature forms.
This is the simplest processing pattern that would explain the additional, slowest
migrating form only seen undernonreducing SDS-PAGE. Given the conservation
of the four cysteines throughout this family ofsecreted polypeptides and knowing
the disulfide structure of OTG, it seems likely that IP-10 would contain two
internal disulfide crossbridges. This hypothesis awaits the definitive analysis that
will come from protein purification and subsequent characterization.
Using the affinity-purified antibodies directed against the rIP-10 protein
described in this study, Kaplan et al. in the accompanying study (11), demonstrate
that the IP-10 protein is expressed during the development of a cutaneous
delayed cellular immune response by keratinocytes, endothelial cells, and infil-
trating dermal mononuclear cells. In addition, pronounced IP-10 expression is
seen in the epidermis and dermis on the cutaneous lesions of tuberculoid leprosy
(11) and psoriasis (Gottlieb, A., and A. D. Luster, manuscript in preparation).
Both conditions are associated with keratinocytic proliferation and the influx of
mononuclear cells into the dermis. IP-10's homology to chemotactic and mito-
genic proteins suggests that it may play a role in these cellular changes; this
hypothesis awaits a direct analysis.
Summary
An IFN-y-inducible protein, IP-10, has previously (4, 10) been described to
belong to a gene family of chemotactic and mitogenic proteins, associated with
inflammation and proliferation. Biochemical characterization of this predicted
protein has been pursued through the development of polyclonal monospecific
antisera to recombinant protein and synthetic peptides. These reagents establish
that the IP-10 protein is secreted from a variety of cells (endothelial, monocyte,
fibroblast, and keratinocyte) in response to IFN-y. Posttranslational processing
occurs in the biosynthesis of this protein, resulting in a 6-7-kD species, which
may reflect COOH-terminal cleavage. Pulse-chase studies indicate that this
processing is a rapid event in the primary cell lines studied, completed in the 30-
min labeling period. A model is presented for the processing and secondary
structure of this protein. In an accompanying study, Kaplan, et al. (11) using
these antisera, demonstrate that the IP-10 protein is associated, in vivo, with a
delayed-type hypersensitivity response.
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